nature portfolio

Corresponding author(s):	Linda Brunotte
Last updated by author(s):	Jan 17, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

<.	トつ	1	IC:	ŀι	CS
J	ιa	ı.	I.O.	LΙ	LJ

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on statistics for highgrists contains articles on many of the points above

Software and code

Policy information about availability of computer code

Data collection

LI-COR Image Studio™ (v5.2.5), Visual Molecular Dynamics (VMD; v1.9.3), ZEN (v2.6), MODELLER (v9.19); YASARA structure (v21.6.2 and v21.8.27), LightCycler 480 Gene Scanning Software, LI-COR Image Studio™ (v5.2.5)

Data analysis

ChimeraX (v1.3.), PyMOL Molecular Graphics System (v2.3.0), GraphPad PRISM™ (v7.04), Origin 2022 (v9.9), Ridom SeqSphere+ software (v7), Visual Molecular Dynamics (VMD; v1.9.3), Yasara structure (v21.6.2 and v21.8.27), ZEN (v2.6), MaxQuant (v. 2.0.1.0), ImageJ (v1.53c), Li-COR Image Studio™ (v5.2.5)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The mass spectrometry proteomics data generated in this study have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with

MD simulation data The study made use NCBI: PB1, PB2 and	are available upo of the publicly a PA sequences fr 5EPI, 6QNW, 7NI	om isolates of human, swine and avian IAV origin. Downloaded: PB2 and PB1: 09/15/2017. PA: 10/01/2017. HA, 4WSA, 5D9A, 6T0N, 6TW1, 6T0S, 6T0V, 6SZU, 6T2C, 6T0U, 2VQZ			
	UniprotKB database (UP000000834.fasta version from 10/2016; UP000005640_9606.fasta version from 04/2019). Biochemical data generated in this study are provided in the Source data file.				
biochemical data ger	neracea iii ciiis se	day are provided in the source data life.			
Human rese	arch part	icipants			
		involving human research participants and Sex and Gender in Research.			
	<u> </u>				
Reporting on sex	and gender	n/a			
Population chara	ecteristics	n/a			
Recruitment		n/a			
Ethics oversight		n/a			
Note that full informa	ation on the app	roval of the study protocol must also be provided in the manuscript.			
Field-spe	ecific re	eporting			
<u>-</u>		is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
X Life sciences		Behavioural & social sciences Ecological, evolutionary & environmental sciences			
	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scier	nces sti	udy design			
		e points even when the disclosure is negative.			
Sample size		ere estimated on the basis of previous studies using similar methods, see Chen et al. (DOI:10.1371/journal.ppat.1008034); Giese			
Sample 3126		1038/s41467-017-01112-3); Zhang et al. (DOI: 10.1038/srep43691)			
Data exclusions	No data were	excluded.			
Replication	successfull. In overexpressed	reperiments were performed with at least three independent replicates (unless otherwise stated), with all attempts at replication Figure 5g one replicate of NA vRNA levels for WT could not be determined. Immune fluorescence analyses of A549 cells with plasmids encoding for WT or mutant PB2, PB1 and PA was performed once (Figure 3 l-n). Analysis of protein expression of ding for WT or mutant PB2, PB1 and PA was performed once (Supplementary Fig. 2 a-i).			
Randomization	Randomization	n is not relevant to our study, given that samples were not assigned to any groups.			
Blinding	_	ot relevant for our study. since there are no experiments where investigator bias could affect measurements or data analysis. analyzed using unbiased methods.			

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experiment	tal systems Methods		
n/a Involved in the study	n/a Involved in the study		
Antibodies	ChIP-seq		
Eukaryotic cell lines	Flow cytometry		
Palaeontology and arc			
Animals and other org	— —		
Clinical data			
Dual use research of co	oncern		
Ţ			
Antibodies			
T (C	at anti-HA-Tag (clone 3F10, Roche, Germany), Rabbit anti-NEDD8 (clone Y297, Abcam, UK), Mouse anti-His-Tag (clone HIS.H8, hermo Fisher, USA), Rabbit anti-PB2 (GTX125926, Genetex, USA), Rabbit anti-PB1 (GTX125923, Genetex, USA), Rabbit anti-PA GTX125932, Genetex, USA), Rabbit anti-NP (GTX125989, Genetex, USA), Mouse anti-Strep-Tag (clone GT661, Sigma Aldrich, Germany), Mouse anti-Tubulin (clone DM1A, Sigma Aldrich, Germany),		
a H G H	nti-Mouse IgG-680RD (LI-COR, Bad Homburg, Germany), anti-Mouse IgG - HRP (Cell signaling Technologies, Frankfurt, Germany), nti-Rabbit IgG-800CW (LI-COR, Bad Homburg, Germany), anti-Rabbit IgG - IRP (Cell signaling Technologies, Frankfurt, Germany), anti-Rabbit IgG-Alexa Flour 488 (Thermo Fisher Scientific, Schwerte, iermany), anti-Rabbit IgG-Alexa Flour 568 (Thermo Fisher Scientific, Schwerte, Germany), anti-Rat IgG-800CW (LI-COR, Bad Iomburg, Germany), anti-Rat IgG-Alexa Fluor 488 (Thermo Fisher Cientific, Schwerte, Germany)		
Validation	commercially available antibodies were all validated by suppliers:		
	at anti HA-Tag (clone 3F10, Roche) https://www.sigmaaldrich.com/DE/en/product/roche/12158167001 abbit anti-NEDD8 (clone Y297, Abcam) https://www.abcam.com/nedd8-antibody-y297-ab81264.html?		
	Nouse anti-His-Tag (clone HIS.H8, Thermo Fisher) https://www.thermofisher.com/antibody/product/6x-His-Tag-Antibody-clone-HIS-		
	8-Monoclonal/MA1-21315 abbit anti-PB2 (GTX125926, Genetex) https://www.genetex.com/Product/Detail/Influenza-A-virus-PB2-protein-antibody/		
	TX125926		
	abbit anti-PB1 (GTX125923, Genetex) https://www.genetex.com/Product/Detail/Influenza-A-virus-PB1-protein-antibody/ GTX125923		
R R	inkl2923 abbit anti-PA (GTX125932, Genetex) https://www.genetex.com/Product/Detail/Influenza-A-virus-PA-protein-antibody/GTX125932 abbit anti-NP (GTX125989, Genetex) https://www.genetex.com/Product/Detail/Influenza-A-virus-Nucleoprotein-antibody/ iTX125989		
N	Nouse anti-Strep-Tag (clone GT661, Sigma Aldrich) https://www.sigmaaldrich.com/DE/en/product/sigma/sab2702216		
N	Mouse anti-Tubulin (clone DM1A, Sigma Aldrich) https://www.sigmaaldrich.com/DE/en/product/mm/mabt205		
Eukaryotic cell line:	S S		
Policy information about <u>cell</u>	lines and Sex and Gender in Research		
Cell line source(s)	A549: ATCC; # CCL-185; MDCK II: Merck; #00062107; HEK293T cells: ATTC; CRL-3216. All cells were kindly provided by Prof. Martin Schwemmle (Institute of Virology, Freiburg, Germany)		

Cell line source(s)	A549: ATCC; # CCL-185; MDCK II: Merck; #00062107; HEK293T cells: ATTC; CRL-3216. All cells were kindly provided by Prof. Martin Schwemmle (Institute of Virology, Freiburg, Germany)
Authentication	Cell lines were not authenticated.
Mycoplasma contamination	All cells were tested negative for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)	No commonly misidentified cell lines were used.